Evelena Ontiveros is an Oncology physician. OpenAlex indexes 15 publications with 300 citations (h-index 9); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
210 W Mckinley Ave Ste 1
Decatur, IL 625265858
Telephone
217-876-6600Provider last certified this registry record 12 Nov 2025.
Clinical trials
- Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Sponsor: Roswell Park Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
29 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20257 payments
- E.R. Squibb & Sons, L.L.C.Program year20254 payments
- GlaxoSmithKline, LLC.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
88.4%Iron, parenteral preparations88%Ferric carboxymaltose100%Part B, office-administered≥37 patientsFactor Xa inhibitor0.3%Eliquis52%Xarelto48%Part D≥19 patients+ 3 more classes in this area
Musculoskeletal
4.2%RANK Ligand Inhibitor4%Denosumab100%Part B, office-administered≥12 patientsBisphosphonate0.1%Zoledronic acid100%Part B, office-administered≥15 patients+ 1 more class in this area
Metabolism & gastrointestinal
3.3%Serotonin-3 Receptor Antagonist3%Ondansetron hydrochloride64%Palonosetron hcl29%Ondansetron Hcl6%Ondansetron Odt1%Part D + Part B≥63 patientsProton pump inhibitor0.1%Pantoprazole Sodium79%Omeprazole21%Part D<11 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia
Leukemia Research Reports
2017 - Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib
Case Reports in Hematology
2017 - Intensive Chemotherapy vs. Hypomethylating Agents in Older Adults with Newly Diagnosed High-Risk Acute Myeloid Leukemia: A Single Center Experience
Clinical Lymphoma Myeloma & Leukemia
2017
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”